Zhu Yinghong, Yang Qiaohui, Yang Qin, He Yanjuan, Zhou Wen
Haihe Laboratory of Cell Ecosystem, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Geriatric Disorders, Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China.
Key Laboratory for Carcinogenesis and Invasion, Chinese Ministry of Education, Key Laboratory of Carcinogenesis, Chinese Ministry of Health, Cancer Research Institute, School of Basic Medical Sciences, Central South University, Changsha 410008, China.
Cancers (Basel). 2023 Apr 13;15(8):2284. doi: 10.3390/cancers15082284.
Hematological malignancies are diverse, with high malignancy characteristics, poor prognoses, and high mortality rates. The development of hematological malignancies is driven by genetic factors, tumor microenvironment factors, or metabolic factors; however, even when considering all of these factors, one still cannot fully estimate the risk of hematological malignancies. Several recent studies have demonstrated an intimate connection between intestinal microbes and the progression of hematological malignancies, and gut microbes play a primary role in the initiation and progression of hematological tumors through direct and indirect mechanisms. Thus, we summarize the correlation between intestinal microbes and hematological malignancies' onset, progression, and therapeutic effect in order to better understand how intestinal microbes affect their initiation and progression, especially in leukemia, lymphoma, and multiple myeloma, which may provide potential therapeutic targets for improving the survival of patients with hematological malignancies.
血液系统恶性肿瘤种类繁多，具有高恶性特征、预后差和死亡率高的特点。血液系统恶性肿瘤的发生是由遗传因素、肿瘤微环境因素或代谢因素驱动的；然而，即使考虑到所有这些因素，人们仍然无法完全估计血液系统恶性肿瘤的风险。最近的几项研究表明肠道微生物与血液系统恶性肿瘤的进展之间存在密切联系，并且肠道微生物通过直接和间接机制在血液系统肿瘤的发生和进展中起主要作用。因此，我们总结肠道微生物与血液系统恶性肿瘤的发生、进展及治疗效果之间的相关性，以便更好地了解肠道微生物如何影响其发生和进展，特别是在白血病、淋巴瘤和多发性骨髓瘤中，这可能为提高血液系统恶性肿瘤患者的生存率提供潜在的治疗靶点。
